Abstract: Described herein are peptides and peptide-antibody fusions that bind to the SARS-CoV-2 S protein and the receptor binding domain (RED), and methods for using the compositions containing these antibodies in the treatment of COVID-19, Specifically, we developed novel CoV-2 S protein binding peptides making use of a naïve phage-displayed 16mer peptide library—wherein the CoV-2 S protein binding peptides bind epitopes in both the RBD and S protein outside of the RBD. In addition, we show that fusion of these peptides to the N-terminus of nAbs improves their apparent affinity, potency and breadth of neutralization, without compromising their developability profile, Thus, these peptides represent a novel class of SARS-CoV-2 S protein binders, which can be formatted in various ways to improve functional properties of nAbs to be used in the treatment of many different diseases.